BridgeMD
Compares treatment options for LARS - Low Anterior Resection Syndrome
Official title 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
ClinicalTrials.gov ID: NCT05577845
What this study is testing
What is Ramosetron?
Ramosetron is an investigational medicine, being studied as a potential treatment for lars - low anterior resection syndrome.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- mid and low rectal cancer (AV\<15cm)
- stage II, III, preop long-course CCRT, then ileostomy repair
- about 1\~12 months after operation (no stomy)
- about 1\~6 months after ileostomy repair
- major LARS
You likely can't join if
- recurred rectal cancer
- stage IV
- uncontrolled preoperative fecal incontinence or constipation
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, Jongro-gu, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, Jongro-gu, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.